New molecules can offer breakthrough in fight against antibiotic resistance

Researchers at Umeå University have identified a new class of antibacterial compounds, named TriPcides, capable of targeting *Staphylococcus aureus*—including antibiotic-resistant strains such as MRSA. The compounds disrupt bacterial cell membranes and interfere with infection processes, demonstrating effectiveness against Gram-positive bacteria in laboratory tests. An important breakthrough is their ability to eliminate persister cells—dormant bacteria that often survive antibiotic treatment and cause infection relapse. These cells enter a metabolically inactive state, evading conventional therapies, but the TriPcides showed activity against them, according to Fredrik Almqvist, Professor at the Department of Chemistry. The discovery addresses a critical global health challenge: antibiotic resistance, which complicates infections, prolongs hospital stays, and increases mortality. Existing drugs are increasingly ineffective, underscoring the urgent need for alternative treatments. The study, an international collaboration involving Umeå University’s Umeå Centre for Microbial Research (UCMR), highlights the potential of TriPcides to complement or replace current antibiotics. While clinical application requires further research, the findings offer hope for more effective treatments that could reduce healthcare burdens. Almqvist noted that bacteria in the study did not easily develop resistance to these synthetic compounds, and no existing resistance was observed in clinical isolates. The research marks a step forward in combating infectious diseases with new antibiotic strategies.